Innovations In Clinical Neuroscience

MAR-APR 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: https://innovationscns.epubxp.com/i/964320

Contents of this Issue

Navigation

Page 13 of 55

14 ICNS INNOVATIONS IN CLINICAL NEUROSCIENCE March-April 2018 • Volume 15 • Number 3–4 in serious individual adverse events, while LAIs were associated with significantly lower prolactin change. 11 Although the non-double-blind method, small sample size, and insufficient follow-up intervals were limitations in this study, serum prolactin levels in patients switched from daily to once-monthly aripiprazole might be consistently useful to estimate D 2 receptor occupancy and confirm safety treatment with LAI in a clinical setting. References 1. Iyo M, Tadokoro S, Kanahara N, et al. Optimal extent of dopamine D 2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013;33: 398–404. 2. Arakawa R, Okumura M, Ito H, et al. Positron emission tomography measurement of dopamine D receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic- induced hyperprolactinemia. J Clin Psychiatry. 2010;71:1131–7. 3. Nakamura M, Nagamine T, Sato G, et al. Prolactin levels after switching to paliperidone palmitate in patients with schizophrenia. Innov Clin Neurosci. 2016;13:28–30. 4. Nakamura M, Nagamine T. Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient. Asia Pac Psychiatry. 2018 Mar; 10(1). doi: 10.1111/appy.12300. 5. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44:179–187. 6. Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple dose study. Schizophr Res. 2013;150:281–288. 7. Wakamatsu A, Aoki K, Sakiyama Y, et al. Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics. Innov Clin Neurosci. 2013;10:23–30. 8. Nakamura M, Nagamine T. Hypoprolactinemia and extrapyramidal symptoms in male schizophrenia or psychotic affective disorder patients treated with aripiprazole. Clin Neuropsychopharmacol Ther. 2012;3:18–22. 9. Markowitz M, Fu DJ, Levitan B, et al. Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry. 2013;12:22. 10. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non- inferiority study. Br J Psychiatry. 2014;205:135–44. 11. Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176:220–230. With regard, Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Dr. Nakamura is with the Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital, Hiroshima, Japan. Dr. Nagamine is with the Department of Psychiatric Internal Medicine, Sunlight Brain Research Center, Yamaguchi, Japan. Correspondence: Masaru Nakamura, MD, PhD; Email:info@kusatsu-hp.or.jp. Funding/financial disclosures: No funding was provided for the preparation of this letter. The authors have no conflicts of interest relevant to the content of this letter. ICNS L E T T E R S T O T H E E D I T O R

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - MAR-APR 2018